All In Biotech

Drug Trial Radar · NCT03439137

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Feb 14, 2018

Primary completion

Dec 12, 2018

Study completion Jul 16, 2019

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Feb 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.

Conditions

  • Anemia; Hemodialysis Dependent Chronic Kidney Disease

Interventions

  • MT-6548Drug

    Oral tablet

  • Darbepoetin alfaDrug

    Intravenous administration

  • MT-6548-matching placeboDrug

    Oral tablet

  • Darbepoetin alfa-matching placeboDrug

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Hb Level of Week 20 and Week 24Time frame: Up to Week 24

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Research site

    Aichi, Japan

  • Research site

    Chiba, Japan

  • Research site

    Fukui, Japan

  • Research site

    Fukuoka, Japan

  • Research site

    Fukushima, Japan

  • Research site

    Gunma, Japan

  • Research site

    Hiroshima, Japan

  • Research site

    Hokkaido, Japan

  • Research site

    Hyōgo, Japan

  • Research site

    Ibaraki, Japan

  • Research site

    Kagawa, Japan

  • Research site

    Kagoshima, Japan

  • Research site

    Kanagawa, Japan

  • Research site

    Kumamoto, Japan

  • Research site

    Kyoto, Japan

  • Research site

    Miyagi, Japan

  • Research site

    Nagano, Japan

  • Research site

    Nagasaki, Japan

  • Research site

    Ōita, Japan

  • Research site

    Okayama, Japan

  • Research site

    Okinawa, Japan

  • Research site

    Osaka, Japan

  • Research site

    Saitama, Japan

  • Research site

    Shiga, Japan

  • Research site

    Shizuoka, Japan

  • Research site

    Tokushma, Japan

  • Research site

    Tokyo, Japan

  • Research site

    Yamagata, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.